Preterm Birth Patients Sought By US FDA As Meeting On Treatment Development Looms

With the only FDA-approved treatment off the market, the FDA is looking for ideas for development of new preterm birth treatments.

preterm birth
The FDA/Duke-Margolis meeting on preterm birth drug development is scheduled for late January. • Source: Shutterstock

The US Food and Drug Administration is urgently seeking patients that have experienced preterm birth with the market now devoid of treatments and a workshop on developing new therapies upcoming.

A 30 November post on X, formerly known as Twitter, from the FDA Patient Affairs Office seemed ominous: “US...

Welcome to Pink Sheet

Create an account to read this article

More from R&D

UK HRA Working On ‘Trusted’ Path Forward To Support Simplified Informed Consent

 
• By 

The Health Research Authority is working on a streamlined model for informed consent that maintains people’s trust.

New US FDA Biologics License Pathway Could Be Missing Link To Reduce Animal Testing

 

Akin to the 505(b)(2) NDA, a new biologic pathway could reduce the need for animal testing, FDA toxicologist says. Expanded use of generally accepted scientific knowledge (GASK), which few sponsors have attempted despite a 2023 draft guidance, would also help.

EMA’s PRIME Scheme Explored: Growing Designations - But Are Accelerated Assessments Slipping?

 

While the first six months of the year saw eight new drugs targeting a range of diseases enter the European Medicines Agency’s priority medicines scheme, and three PRIME-designated treatments go on to win EU marketing approval, use of the accelerated assessment mechanism appears to be limited.

Animal Testing: US And EU Regulatory Support Grows For Alternatives, But Validation A Hurdle

 

In this first of a two-part series of articles, US Pharmacopeia CEO Ronald T. Piervincenzi tells the Pink Sheet how the use of alternatives to animal testing in drug development is gaining traction and discusses the challenges that exist.

More from Conferences

Post-BIO Podcast: Thoughts From The Frontlines

Pink Sheet and Scrip journalists reflect on the mood from Boston, the most important takeaways and what’s next for industry.

BIO CEO On Industry And US FDA, Trump’s Vaccine Views And MFN Counter Proposals

 

John Crowley discussed how he prioritizes industry’s many competing challenges in a Pink Sheet interview at the BIO International Convention.

US FDA’s Elsa AI Platform Is Not Guiding Regulatory Decisions, Official Says

 
• By 

Tala Fakhouri said the agency’s use of the AI tool in the review process has generated lots of questions.